LC
NAMS icon

Lindbrook Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Lindbrook Capital’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$921 Buy
+45
New +$1K ﹤0.01% 2485

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Lindbrook Capital's NAMS Position: Q1 2025 in Review

Lindbrook Capital opened a new position in NewAmsterdam Pharma (NAMS) in Q1 2025: 45 shares worth $921. The stake represents ﹤0.01% of the portfolio and ranks #2485 among its holdings.

126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Lindbrook Capital held 45 shares of NewAmsterdam Pharma worth $921 as of Q1 2025.
  • NewAmsterdam Pharma was a new Lindbrook Capital position in Q1 2025.
  • NewAmsterdam Pharma made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2485 holding.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.